PDCD1 and melanoma: Since the approval of Yervoy, a CTLA-4-targeting antibody, for treating melanoma in 2011, immune checkpoint inhibitors (ICIs) such as anti-PD-1 and PD-L1 antibodies have been widely used to treat cancer [1,2].